Molecular diagnostics and targeted therapeutics are emerging as industries that will be driven by the information era; specifically, gaining insight from reliable data from gene expression microarrays, mass spec, 2-D gels, protein-protein or protein-DNA interaction studies, metabolic information, to create interconnected pathways. The knowledge that is driving molecular signatures for diagnosis and pathway-specific therapeutics will be gleaned from experiments and literature to create signature biomarkers for signature molecules. How we can identify and interpret these biomarker patterns is essential to this process. Learn how experts are analyzing the data to expedite product development in areas of drug development and diagnostics to create a new generation of pathway-specific products.